Novel multi-omic biomarkers for diverse populations
Research type
Research Study
Full title
Characterising the added value of multi-omic biomarkers for medication response in early phase clinical trial drug development in diverse populations
IRAS ID
355396
Contact name
Mark Caulfield
Contact email
Sponsor organisation
Queen Mary University of London
Duration of Study in the UK
9 years, 11 months, 30 days
Research summary
Scientists at Queen Mary University of London (QMUL) and Hammersmith Medicines Research (HMR) are running a big study for five years. They want to understand how different people react to medicines. To do this, they will look at three things in our bodies:
Genes (the instructions in our DNA)
Proteins (tiny machines that do important jobs)
Metabolites (small substances that help our bodies work)
By studying all of these, they hope to learn why some medicines work really well for some people but not as well for others.
People who join the study will get some of their genetic results back—these could help doctors choose medicines that work better for them in the future. Afterward, scientists will ask the participants how they feel about getting this information.
Participants will have up to 5 blood samples taken and complete up to 6 surveys during the project.
The study is funded by the Medical Research Council.
REC name
London - Hampstead Research Ethics Committee
REC reference
25/PR/0980
Date of REC Opinion
6 Aug 2025
REC opinion
Further Information Favourable Opinion